Asian Annals Click here to go to Maquet website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Upendra Kaul
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaul, U.
Right arrow Articles by Wasir, H. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kaul, U.
Right arrow Articles by Wasir, H. S.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Coronary disease
Asian Cardiovasc Thorac Ann 2001;9:31-35
© 2001 Asia Publishing EXchange Pte Ltd

ORIGINAL CONTRIBUTION

Abciximab During Rescue Angioplasty After Failed Thrombolysis

Upendra Kaul, MD, Rakesh Sapra, MD, Balbir Singh, MD, Dinesh Sudan, MD, Tapan Ghose, MD, Narayan Shyamsunder Dixit, FRCP, Harbans Singh Wasir, MD

Department of Interventional Cardiology Batra Hospital & Medical Research Centre New Delhi, India
For reprint information contact: Upendra Kaul, MD Tel: 91 11 609 1887 Fax: 91 11 644 3434 email: ukaul{at}del3.vsnl.net.in Department of Interventional Cardiology, Batra Hospital & Medical Research Centre, 1 Tughlakabad Institutional Area, Mehrauli Badarpur Road, New Delhi 110062, India.
Abciximab (a glycoprotein IIb/IIIa inhibitor) was assessed in 16 of 36 patients with acute myocardial infarction who were referred for rescue angioplasty after failed thrombolysis. Baseline clinical and angiographic characteristics were comparable in the abciximab and non-abciximab groups. Coronary stenting was carried out in all patients in the non-abciximab group and in 13 in the abciximab group. Angiographic success was achieved in all patients. Persistence of slow flow was encountered more frequently in the non-abciximab group (30% versus 6.25%, p < 0.05). Stent thrombosis occurred in 2 patients (10%) who were successfully redilated and there was one case of bleeding requiring transfusion in the non-abciximab group; neither of these complications occurred in the abciximab group. Predischarge left ventricular ejection fraction was better in the abciximab group (44% ± 3% versus 36% ± 3%, p < 0.01). All patients were discharged alive and were asymptomatic at the one-month follow-up. Use of abciximab during angioplasty after failed thrombolysis improved angiographic and clinical results without increasing the risk of bleeding, and reduced the incidence of in-hospital complications. Larger studies are warranted to confirm this important observation.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by the Asia Publishing EXchange Ltd.